Schrödinger (SDGR) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
3 Feb, 2026Opening remarks and agenda
Meeting opened by CEO, with introductions of board members, management, legal counsel, and independent auditors.
Rules of conduct and forward-looking statement disclaimers were reviewed.
Board and executive committee updates
Board members and executive team were introduced, including the presence of the Inspector of Election and legal counsel.
Shareholder proposals
Six proposals were presented: election of three Class I directors, advisory vote on executive compensation, amendments to the 2022 Equity Incentive Plan and 2020 Employee Stock Purchase Plan, amendment to the Restated Certificate of Incorporation, and ratification of KPMG LLP as auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Schrödinger
- Q1 2026 saw 12% ACV growth, strong drug discovery revenue, and a major M&A milestone.SDGR
Q1 20266 May 2026 - Board recommends approval of all proposals, including director elections and equity plan amendment.SDGR
Proxy filing28 Apr 2026 - Virtual meeting to vote on directors, compensation, equity plan, and auditor ratification.SDGR
Proxy filing28 Apr 2026 - 23% revenue growth to $255.9M, strong cash, and shift to hosted software drive future profitability.SDGR
Q4 202515 Apr 2026 - Strategic shift to hosted software, AI integration, and new products drive growth and industry impact.SDGR
2026 KeyBanc Capital Markets Healthcare Forum17 Mar 2026 - Transition to ACV, new product launches, and materials science drive growth outlook.SDGR
Leerink Global Healthcare Conference 202610 Mar 2026 - Transition to hosted services and AI-driven innovation drive growth and partnerships in drug discovery.SDGR
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q1 saw strong software growth, clinical progress, and advancing predictive tox initiatives.SDGR
Jefferies Global Healthcare Conference 20253 Feb 2026 - Q2 revenue up 35% to $47.3M; predictive toxicology and clinical pipeline drive growth.SDGR
Q2 20242 Feb 2026